MINNEAPOLIS--(BUSINESS WIRE)--June 12, 2006--Medtronic, Inc. (NYSE:MDT - News) today announced that it has received reimbursement approval in France for the Endeavor® drug-eluting coronary stent (DES) system. The announcement was made following publication in the official French government journal, "Journal Officiel de la Republique Francaise," on June 8, 2006. The company said the stent will be available June 21 to public and private hospitals throughout France, providing physicians and patients with a clinically-proven option for the treatment of coronary artery disease in one of the largest DES markets in Europe.
